The global Alzheimer’s drugs market size reached US$ 7.7 Billion in 2023. Looking forward, the market is projected to reach US$ 12.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.44% during 2023-2032. The rising prevalence of Alzheimer’s disease, numerous advancements in drug development, and increasing public and private funding for neurodegenerative disease research are some of the major factors propelling the market.
Alzheimer’s drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer’s disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer’s disease.
They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.
The rising prevalence of Alzheimer’s disease that necessitates effective treatments will stimulate the growth of the Alzheimer’s drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth.
Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer’s disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.
Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer’s disease.
Moreover, regulatory agencies are streamlining approval processes for Alzheimer’s drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer’s treatments to the market, addressing a pressing global healthcare need.
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes donepezil, galantamine, rivastigmine, memantine, and others. According to the report, donepezil represented the largest segment.
Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer’s disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer’s, such as memory loss, confusion, and problems with thinking and reasoning.
Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer’s to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer’s continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer’s drugs market.
A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, online stores, and others. According to the report, hospital pharmacy accounted for the largest market share.
Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer’s medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer’s drugs reach the right individuals at the right time.
Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer’s drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer’s primarily affects older individuals. This demographic trend increases the demand for Alzheimer’s drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer’s drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.
Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer’s disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer’s drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.
Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer’s. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.
In March 2021, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer’s disease. This expansion underscores their shared commitment to addressing one of the most challenging and pressing healthcare issues of our time. Both companies bring unique strengths to the table: Biogen's expertise in neuroscience and drug development, combined with Eisai's deep-rooted knowledge in the field of dementia and Alzheimer’s disease, creates a powerful synergy.
In September 2022, Eisai Co., Ltd. and Biogen Inc. reported positive topline results from their global Phase 3 Clarity AD clinical trial of lecanemab. Lecanemab is an investigational antibody designed to target amyloid beta (Aβ) protofibrils, and it holds promise as a potential treatment for individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease. This development marks a significant milestone in the pursuit of effective Alzheimer’s treatments. The positive results suggest that lecanemab has shown potential in addressing the underlying pathology of Alzheimer’s disease by targeting Aβ protofibrils, which are thought to contribute to disease progression.
Alzheimer’s drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer’s disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer’s disease.
They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.
The rising prevalence of Alzheimer’s disease that necessitates effective treatments will stimulate the growth of the Alzheimer’s drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth.
Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer’s disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.
Alzheimer’s Drugs Market Trends/Drivers
Rising prevalence of the disease
The escalating prevalence of Alzheimer’s disease is one of the key factors supporting the market growth. This can be attributed to the rapidly aging population worldwide. As people live longer, the incidence of age-related neurodegenerative disorders, including Alzheimer’s, has surged. This demographic shift places an ever-increasing burden on global healthcare systems and necessitates effective treatments.Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer’s disease.
Rapid advancements in research
Advances in the understanding of Alzheimer’s disease at the molecular and cellular levels are pivotal drivers in the market. Researchers are unraveling the complex mechanisms behind the disease, including the role of amyloid plaques and tau protein tangles in brain degeneration. These insights provide valuable targets for drug development. Additionally, genetics research is revealing the hereditary factors that increase susceptibility to Alzheimer’s, further guiding drug discovery efforts. Cutting-edge technologies, such as genomics, neuroimaging, and biomarker analysis, are facilitating clinical trials and drug efficacy assessments. These research-driven developments are instrumental in expanding the repertoire of potential Alzheimer’s drugs and enhancing their effectiveness, offering hope for improved patient outcomes.Increasing government funding and support
Governments and healthcare organizations across the globe are increasingly recognizing Alzheimer’s disease as a public health crisis. The substantial economic and social impact of the disease, including caregiver burden and healthcare costs, has led to a rise in funding for Alzheimer’s research and drug development initiatives. Government grants, research partnerships, and incentives for pharmaceutical companies have become more prevalent. This financial support bolsters ongoing research efforts and encourages the pharmaceutical industry to invest in Alzheimer’s drug development.Moreover, regulatory agencies are streamlining approval processes for Alzheimer’s drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer’s treatments to the market, addressing a pressing global healthcare need.
Alzheimer’s Drugs Industry Segmentation
This report provides an analysis of the key trends in each sub-segment of the global Alzheimer’s drugs market report, along with forecasts at the global, regional and country levels for 2024-2032. The report has categorized the market based on drug class and distribution channel.Breakup by Drug Class:
- Donepezil
- Galantamine
- Rivastigmine
- Memantine
- Others
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes donepezil, galantamine, rivastigmine, memantine, and others. According to the report, donepezil represented the largest segment.
Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer’s disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer’s, such as memory loss, confusion, and problems with thinking and reasoning.
Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer’s to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer’s continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer’s drugs market.
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Others
A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, online stores, and others. According to the report, hospital pharmacy accounted for the largest market share.
Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer’s medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer’s drugs reach the right individuals at the right time.
Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer’s drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer’s primarily affects older individuals. This demographic trend increases the demand for Alzheimer’s drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer’s drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.
Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer’s disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer’s drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.
Competitive Landscape
Key players in the Alzheimer’s drugs industry have been instrumental in driving recent innovations. Notably, a groundbreaking FDA-approved drug from one of these major pharmaceutical companies directly targets amyloid plaques, marking a significant advancement in Alzheimer’s treatment. Other key players are pioneering therapies that enhance amyloid clearance and simultaneously address tau pathology, both of which have shown promise in clinical trials. Beyond traditional drug development, these companies are exploring innovative approaches, including anti-inflammatory drugs, to combat neuroinflammation associated with Alzheimer’s.Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer’s. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.
Some of the key players in the market include:
- AbbVie Inc.
- AstraZeneca PLC
- Biogen Inc.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Eli Lilly and Company
- H. Lundbeck A/S
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Novartis AG
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc
- Teva Pharmaceutical Industries Limited
Recent Developments
In July 2023, AbbVie Inc., a leading global biopharmaceutical company, announced the expansion of its strategic collaboration with Calibr, a nonprofit drug discovery division of Scripps Research. This collaboration aims to propel the development of multiple preclinical and early-stage clinical assets in the field of biopharmaceuticals. Building upon their existing partnership, this expansion signifies a commitment to advancing innovative therapies for various diseases.In March 2021, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer’s disease. This expansion underscores their shared commitment to addressing one of the most challenging and pressing healthcare issues of our time. Both companies bring unique strengths to the table: Biogen's expertise in neuroscience and drug development, combined with Eisai's deep-rooted knowledge in the field of dementia and Alzheimer’s disease, creates a powerful synergy.
In September 2022, Eisai Co., Ltd. and Biogen Inc. reported positive topline results from their global Phase 3 Clarity AD clinical trial of lecanemab. Lecanemab is an investigational antibody designed to target amyloid beta (Aβ) protofibrils, and it holds promise as a potential treatment for individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease. This development marks a significant milestone in the pursuit of effective Alzheimer’s treatments. The positive results suggest that lecanemab has shown potential in addressing the underlying pathology of Alzheimer’s disease by targeting Aβ protofibrils, which are thought to contribute to disease progression.
Key Questions Answered in This Report
- How has the global alzheimer’s drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global alzheimer’s drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global alzheimer’s drugs market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Alzheimer’s Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Distribution Channel
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AbbVie Inc.
- AstraZeneca PLC
- Biogen Inc.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Eli Lilly and Company
- H. Lundbeck A/S
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Novartis AG
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc
- Teva Pharmaceutical Industries Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 7.7 Billion |
| Forecasted Market Value ( USD | $ 12.4 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
